D

Day One Biopharmaceuticals Inc
NASDAQ:DAWN

Watchlist Manager
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Watchlist
Price: 13.72 USD 2.85% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Day One Biopharmaceuticals Inc?
Write Note

Gross Margin
Day One Biopharmaceuticals Inc

97.8%
Current
15%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
97.8%
=
Gross Profit
99.7m
/
Revenue
102m

Gross Margin Across Competitors

Country US
Market Cap 1.4B USD
Gross Margin
98%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 312.7B USD
Gross Margin
67%
Country US
Market Cap 158.3B USD
Gross Margin
60%
Country US
Market Cap 116.2B USD
Gross Margin
86%
Country US
Market Cap 112.4B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 133.6B AUD
Gross Margin
52%
Country US
Market Cap 81.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.8B EUR
Gross Margin
89%
No Stocks Found

Day One Biopharmaceuticals Inc
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in South San Francisco, California and currently employs 42 full-time employees. The company went IPO on 2021-05-27. The company is focused on developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers. The company seeks to identify, acquires, and develops product candidates that target high-value oncogenic drivers in cancers with unmet need, with an initial focus on pediatric patients. Its lead product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Tovorafenib is also used for the treatment of low-grade gliomas (LGGs). Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a key signaling node in the MAPK pathway. The company has initiated a phase II trial of tovorafenib for pediatric patients with relapsed or progressive low-grade glioma (pLGG), the common brain tumor diagnosed in children.

DAWN Intrinsic Value
18.85 USD
Undervaluation 27%
Intrinsic Value
Price
D

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
97.8%
=
Gross Profit
99.7m
/
Revenue
102m
What is the Gross Margin of Day One Biopharmaceuticals Inc?

Based on Day One Biopharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 97.8%.